Introduction clearance and a long half-life (70-80 h) [10, 11] . Although donepezil is metabolized primarily by the P-450 isoenzyme Donepezil HCl (also known as E2020 or AriceptA, the registered trademark of Eisai Co. Ltd, Tokyo, Japan) is a CYP-3A4, and to a lesser extent by CYP-2D6, compromised hepatic function does not significantly affect its pharmacopiperidine-based inhibitor of the enzyme acetylcholinesterase (AChE) [1, 2] . It has recently been approved for marketing kinetic profile [12] .
Since its recognition as a broncodilator almost 50 years in the USA, Canada and several EU member states, including the UK, for the symptomatic treatment of mild-moderate ago, theophylline, a methylxanthine alkaloid, has played an important role in the management of both acute and chronic Alzheimer's disease. In vitro studies have demonstrated that donepezil has a significantly greater degree of selectivity for reversible airway obstruction, in particular asthma and chronic bronchitis. However, it has a narrow safety window, AChE in the central nervous system (CNS) than for butyrylcholinesterase (BuChE) in the periphery [2, 3] .
which, along with its variability in disposition, makes dosing difficult to predict and toxicity difficult to prevent. Symptoms Clinical trials undertaken in the USA and Europe have demonstrated that donepezil (5 mg or 10 mg, once daily) of toxicity include tachycardia, severe restlessness, agitation, nausea and vomiting, particularly at high blood concensignificantly improves cognitive and global function in patients with Alzheimer's disease [4] [5] [6] [7] . Furthermore, these trations [13, 14] .
The physical status of a patient can greatly alter theophylline studies have shown that donepezil is well tolerated and is not associated with the hepatotoxicity that is commonly metabolism and/or elimination, resulting in toxic plasma levels. Several disease states, as well as advanced age, smoking and seen with acridine-based cholinesterase inhibitors, such as tacrine [8] . Phase I studies conducted in the USA [9] pulmonary oedema and congestive heart failure [13, 14] .
Theophylline is prone to clinically significant interactions of the titration phase, there was a 1-week, drug-free washout period prior to initiation of the first treatment period. with other drugs. For instance, the clearance of theophylline is increased substantially during the concomitant adminis-
The two treatments administered in this study were: (1) theophylline, and (2) the combination of theophylline+ tration of phenytoin [15] . Rifampin and oral contraceptives produce smaller but appreciable increases in theophylline donepezil (5 mg, once daily), with subjects receiving the treatments in random order. The 5 mg day −1 dose of clearance, whereas cimetidine and erythromycin have been reported to reduce the clearance of theophylline [15] . With donepezil chosen for this study is the approved recommended starting dose in the USA and Europe, and was selected on this in mind, the present study was designed to determine whether concurrent, multiple-dose administration of susthe basis of its clinical efficacy [4, 6, 7] . Treatment periods were 10 days in duration and separated by a 3-week, drugtained-release theophylline with donepezil would produce clinically relevant changes in theophylline pharmacokinetics free washout period. During the first 4 days of each treatment period, the dose of theophylline was re-titrated in healthy volunteers.
to the intended final dose in order to reduce the incidence of adverse events. This titration scheme was as follows: Methods administration of a quarter of the final theophylline dose for the first 2 days, half the final dose for the next 2 days and This study was conducted in accordance with Good Clinical the full dose for the remaining 6 days of each 10-day Practice Guidelines issued by the European Commission treatment period. The theophylline dose was taken twice (1990). The protocol was approved by an independent ethics daily. Each day at 08:00 h and following an 8-h overnight committee and written informed consent was obtained from fast, subjects were administered theophylline alone or each volunteer prior to participation in any study activities.
theophylline+donepezil, depending on the treatment being administered, with 240 ml of water. Subjects were then permitted to return home, where they took the remainder Subjects of their daily theophylline dose at 20:00 h. The study population comprised 12 healthy male subjects Subjects were prohibited from taking any other medibetween 18 and 36 years of age who were within 15% of cation, including non-prescription preparations, from 48 h normal weight for their height and body build, based on prior to entering the study until completion of the safety the Metropolitan Insurance Company Height and Weight monitoring visit 2 weeks after the last dose of trial Tables (1983) . The study subjects were all non-smokers and medication. Subjects abstained from alcohol and caffeineeach had normal blood pressure and ECG at screening.
containing drinks and food from 24 h prior to the start until Subjects with evidence of clinically significant cardiovascular, completion of each study period. respiratory, gastrointestinal, hepatic, endocrine, renal, neurological, psychiatric and/or haematological disease were Sample collection and analysis excluded from the trial. Subjects with a history of severe adverse drug reactions or leucopenia, severe or multiple Venous blood samples for the determination of theophylline allergies or habitual drug and/or alcohol abuse were also concentrations were taken at 0, 2, 4, 6, 8, 10, 12, 14, 16, excluded from entering the trial, as were those who had 18, 20, 22 and 24 h after the morning dose. Additional 0-participated in other drug trials in the previous 3 months.
and 24-h blood samples were collected for the determination of donepezil plasma concentrations. Theophylline C min values were measured on days 2, 4, Protocol 6, 7, 8 and 9, approximately 12 h after dose administration. Theophylline was analysed in plasma after solid-phase This was an open-label, randomized, two-period, balanced crossover study. Prior to initiation of the first treatment extraction, using a standard high-performance liquid chromatography (HPLC) method with UV detection. The lower period, a 1-week pre-trial titration was conducted to determine the dose of theophylline needed to achieve limit of quantification was 0.74 mg l −1 . Titration-phase concentrations of theophylline were assessed using the plasma concentrations within the accepted therapeutic range of 10-20 mg l −1 for each subject. During this titration Beckman Synchron CX5 theophylline reagent (P/N 442897). There was good correlation between this method phase, subjects attended the clinic each day at 08:00 h to receive their daily dose of theophylline (TheoDurA, Astra and the HPLC assay used to measure concentrations during the treatment periods. Pharmaceuticals Ltd). On alternate days, their trough ( predose) plasma theophylline levels (C min ) were measured. The starting dose of theophylline was 200 mg, twice daily. This
Pharmacokinetic assessments was titrated upwards every second day according to the measured plasma levels in order to achieve the target Pharmacokinetic parameters for theophylline were estimated using model-independent methods. The data were analysed theophylline C min of approximately 10 mg l −1 . In cases where C min was below 5 mg l −1 , the dose of theophylline separately for the 0-12 h and 12-24 h dosing intervals. Peak plasma concentration (C max ) and the time at which peak was doubled. For values of C min between 5 mg l −1 and 10 mg l −1 , a proportionate adjustment was made according plasma concentration occurred (t max ) were obtained from inspection of the plasma concentration-time curves, with to availability of different-sized tablets. Volunteers were excluded from the study if they presented with unacceptable t max recorded separately for each dose of theophylline. The interdosing area under the plasma concentration-time curve side-effects during the titration phase. Following completion (AUC) was estimated using the linear trapezoidal approxiPharmacokinetics of theophylline mation for the intervals 0-12 h (AUC (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) ) and 12-24 h
The pharmacokinetic parameters for theophylline alone and (AUC (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) ).
in the presence of donepezil are summarized in Table 1 . No statistically significant differences in theophylline pharmacokinetics were observed whether theophylline was adminiSafety assessments stered alone or concurrently with donepezil. The values (±SD) of C max (11.45±1.52 and 11.01±1.45 mg l −1 ), All adverse events experienced by the subjects and/or and AUC (0-12) (112.0±15.0 and 113.0±18.0 mg h l −1 ) observed or elicited during physical examination were were virtually identical for the theophylline and the recorded together with times of onset and cessation, and an theophylline+donepezil groups, respectively. The 90% assessment of their severity and causality. Systolic and confidence intervals for the ratios of C max and AUC for the diastolic blood pressure and pulse rate were monitored at theophylline+donepezil group relative to the theophylline each visit according to the guidelines of the British only group were close to one (Table 1 ). There were no Hypertension Society. Measurements were taken after the statistically significant treatment-by-period interactions for subject had been sitting for 5 min and standing for 2 min.
any of the pharmacokinetic parameters. Plasma concenThe point of disappearance of Korotkoff 's phase V sounds tration-time profiles for theophylline alone and theophylline was used to determine diastolic pressure. A standard 12-lead in the presence of donepezil are presented in Figure 1 . ECG was recorded at the screening visit and on completion of the trial.
Routine haematology, clinical chemistry and urinalysis Safety tests were performed prior to and 24 h after drug adminisBoth treatments were well tolerated and no clinically tration on day 10 of both treatment periods. Haematological significant adverse events were reported during the course assessments included haemoglobin, haematocrit, red blood of the study. Those events that were reported were mild in cell count, platelet count, white blood cell count and severity and transient. When theophylline was administered differential. Clinical chemistry included liver function alone, adverse events included nausea, headache, dizziness (aspartate transaminase, alanine transaminase, gamma-glutaand feelings of agitation. During the theophylline+donepezil myl transferase, alkaline phosphatase, total bilirubin), renal treatment phase, they included nausea, light-headedness, function (urea, creatinine, uric acid), metabolic status insomnia, heart palpitations and pruritus. (glucose, total protein, albumin, globulin) and blood
No clinically significant changes in vital signs, ECG electrolytes (sodium, potassium, chloride, bicarbonate, calparameters or clinical laboratory tests were observed. cium, phosphate). Routine urinalysis (Bayer MultistixA) was also performed ( pH, glucose, protein, haemoglobin or blood, ketones), together with specific gravity and microDiscussion scopic examination of the urine sediment.
The objective of this study was to investigate the possibility of a pharmacological interaction between donepezil and Statistical analysis theophylline following concurrent multiple-dose administration of these drugs in healthy volunteers. This is an C max and AUC for theophylline administered alone and in important study in view of the potential severity of combination with donepezil were compared using analysis theophylline toxicity coupled with the reduction in theoof variance (ANOVA). The analysis was undertaken on logphylline clearance in the elderly [16] , the target population transformed data using the GLM procedure of the SAS for for donepezil. The rate of decrease in theophylline clearance Windows 6.10 software (SAS Institute Inc., Cary, North has been estimated to be 1.25% per year between the ages Carolina, USA). It included factors for subject, treatment, of 18 and 77, and the average reduction in theophylline period and treatment-by-period interaction. The Wilcoxon clearance in elderly relative to young healthy volunteers is rank sums test was used to compare t max between the 34% [17]. treatment regimens.
Various pharmacokinetic interactions are known to exist between theophylline and commonly used drugs. Perhaps the most serious of these is the interaction observed with Results the quinolone antibiotics, enoxacin and ciprofloxacin, both of which substantially reduce the clearance of theophylline.
Subjects
In some patients, this has resulted in plasma concentrations of theophylline above the generally accepted level of Twenty-six volunteers were screened: 16 entered the dose titration period and 13 were recruited into the study.
20 mg l −1 [18] . This pharmacokinetic interaction precipitates theophylline-induced convulsions which, in some cases, Subjects were between 19 and 36 years of age (median 24 years); 63 and 101 kg in weight (median 73 kg ); and are difficult to control with anticonvulsant therapy [13] . Although such interactions between theophylline and other between 174 and 194 cm in height (median 181 cm).
One subject had a positive drug screen during the study drugs have been identified, it was anticipated that concurrent administration of donepezil would not alter the pharmacoand was withdrawn from further treatment. Data from the remaining 12 volunteers who completed all phases of the kinetics of theophylline in this study. This assumption was based on findings from in vitro studies with donepezil study were used in the pharmacokinetic analyses. than 100 mm. In addition, the mean k i values for CYP-3A4 are more than 280-fold lower than the lowest k i value
